# Poster 18

# Aminoxanthones as building blocks for the development of BINOL-based chemosensors

<u>A. R. Rocha-Nunes</u><sup>1,\*</sup>, M. M. P. Borges<sup>1</sup>, V. M. F. Gonçalves<sup>1,2</sup>, M. E. Tiritan<sup>1,3,4</sup> and E. M. P. Silva<sup>1,5</sup>

- <sup>1</sup> TOXRUN-Toxicology Research Unit, University Institute of Health Sciences, CESPU, CRL, 4585-116 Gandra, Portugal
- <sup>2</sup> UNIPRO Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), CESPU, 4585-116 Gandra, Portugal.
- <sup>3</sup> Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
- <sup>4</sup> CIIMAR—Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Novo Edifício do Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos, S/N, 4450-208 Matosinhos, Portugal
- <sup>5</sup> LAQV, REQUIMTE, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal

\* Correspondence: a31605@alunos.cespu.pt

## Abstract

Background: The existence of D-amino acids (D-aa) in human brain is known for a long time, but only recent findings revealed they are neuro-active and can be therapeutically useful if detected in initial stages of Alzheimer Disease (AD) cognitive decline [1]. D-serine and D/L serine ratio in serum have been proposed as biomarkers for AD progression. Knowledge related to the role of D-aa in AD pathogenesis will facilitate novel therapeutic treatments and hence, improve patient's quality of life. An accurate, timely diagnosis and simple method is crucial to access early treatments and the xanthone scaffold has the desirable photophysical properties to be explore as fluorophores. Objective: Develop chiral xanthone derivative-based fluorophores as enantioselective probes for detection and quantification of D-aa and D/L aa ratios for AD diagnoses. Methods: To develop the new xanthone-based chiral derivatives, a strategy based in the synthesis of a xanthone containing a maleimide moiety (MX) obtained from an aminoxanthone (XNH2) was envisioned. The MX could then act as Michael acceptor for the reaction with 1,1'-bi-2-naphthol (BINOL), the chiral moiety that will allow the enantioselective interactions with aa. Results: The synthesis of XNH2 was achieved in two steps: nitration reaction of the xanthone with  $KNO_3$  in  $H_2SO_4$ followed by reduction with SnCl<sub>2</sub> in concentrated HCl [2,3]. The product was recrystallized in ethanol and allowed to react with maleic anhydride followed by reaction with sodium acetate in acetic anhydride to produce the MX derivative. Finally, the 1,4-addition of BINOL to MX was performed [2,3]. Structure elucidation and spectroscopic characterization of the xanthone-BINOL derivative are ongoing. Conclusions: The aminoxanthone was successfully employed for the synthesis of the maleimide intermediate that allowed the conjugation with the BINOL chiral moiety. The spectroscopy studies are in progress, but preliminary results revealed the potential use of the new molecule as a fluorescence probe.

Keywords: chirality; enantioselectivity; fluorescence; amino acids; neurodegenerative diseases

### Acknowledgments

This research was funded by GI2-CESPU, grant number XANTAAL\_GI2-CESPU\_2022.

#### References

- Seckler, J. M.; Lewis, S. J. Advances in D-amino acids in neurological research. *Int J Mol Sci* 2020, *21*, 7325.
   Grzelakowska, A.; Kolińska, J.; Zakłos-Szyda, M.; Sokołowska, J. Novel fluorescent probes for L-cysteine
- based on the xanthone skeleton. J Photochem Photobiol A: Chem 2020, 387, 112153.
  Pace, T. C. S.; Monahan, S. L.; MacRae, A. I.; Kaila, M.; Bohne, C. Photophysics of aminoxanthone derivatives
- 3. Pace, T. C. S.; Monahan, S. L.; MacRae, A. I.; Kaila, M.; Bohne, C. Photophysics of aminoxanthone derivatives and their application as binding probes for DNA. *Photochem Photobiol* **2006**, 82, 78-87.



In *Scientific Letters*, works are published under a CC-BY license (Creative Commons Attribution 4.0 International License at <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use at <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>)